Helgadottir, H., Capone, M., Piccinini, C., Piccin, L., Rutkowski, P., Ferraresi, V., Arance, A. M., Guida, M., Maiello, E., Gogas, H., Quaglino, P., Lebbé, C., Spagnolo, F., Vitale, M. G., Melero, I., Bergqvist, M., Giannarelli, D., Dummer, R., Palmieri, G., Ascierto, P. A. (2025). Serum thymidine kinase activity (TKa) as a potential biomarker in the sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma (SECOMBIT) trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.9522